What Do Investors Actually Look for When Valuing Your Startup?

Here's something nobody tells first-time founders: when an investor sits across from you at pre-seed or seed stage, they're not primarily looking at your financials. They're looking at you, your evidence, and whether the story you're telling matches what the market is actually doing.

This matters because most founders spend the wrong amount of time preparing the wrong things. They polish the deck, rehearse the TAM slide, and build financial projections that everyone in the room knows are fiction. Meanwhile the investor is quietly making a judgment about five completely different things.

Here's what those five things actually are and how they affect the number you'll be offered.

If you're an established business owner rather than a startup founder, our blog post on how much your business is worth covers the valuation methods that apply to you.

First, understand why early-stage valuation is different

At a mature business, valuation is mostly math. You take the earnings, apply an industry multiple, and arrive at a range. The subjectivity is in the multiple, not the method.

At pre-seed and seed stage, the math barely exists. You might have no revenue, no customers, and a product that's still being built. Traditional valuation methods, EBITDA multiples, discounted cash flows are essentially useless when there's nothing to discount.

So investors switch frameworks. Instead of valuing what the business has produced, they value what they believe it could produce and then they discount that future value heavily for risk. The discount rate at pre-seed is brutal. Investors know most early stage companies don't make it, so they need to believe in the ones that do with real conviction.

That conviction comes from evidence. Not projections. Evidence.

What investors actually evaluate at pre-seed

The founding team, and it's not what you think

Every investor says team is the most important thing, which is true but also vague enough to be useless. What they're actually looking for is more specific.

They want to see that you understand this problem better than anyone else in the room, not because you researched it, but because you've lived it, built in the space before, or have access to the market that others don't. The question they're asking is: why is this team the right team to solve this specific problem?

A founder with a track record in the same space, even a partial one, commands a meaningfully higher valuation than an equally smart founder approaching the space cold. At pre-seed, according to the data, the founding team is the single biggest driver of valuation. When there's nothing else to evaluate, the investor is essentially betting on the people.

What depresses valuation at this stage: founders who can't clearly articulate why they are specifically the right people, solo founders without clear plans to build a team, or founding teams with identical skillsets and obvious gaps.

Evidence of real demand, not agreement that the problem exists

There's a crucial distinction that most founders miss: people agreeing that a problem is real is not the same as people demonstrating through their behavior that they want it solved.

User interviews where everyone says "yes this is a problem" are close to worthless as investor evidence. What moves the needle is behavioral proof, people who signed up for a waitlist and actually showed up, customers who paid even a small amount for an early version, pilots that someone fought to get approved internally, or usage data that shows people coming back without being pushed.

The median pre-seed valuation as of late 2025 was around $7.7M according to PitchBook data. But that number is almost meaningless for your specific situation, what matters is whether you can show evidence that narrows the gap between "interesting idea" and "real business." Every piece of behavioral evidence you have widens your valuation range upward.

Market size, but the right kind of big

Investors need to believe that if your startup succeeds, the outcome is large enough to matter. A venture investor writing a check needs to imagine a path to a significant return, which means they need to believe the total addressable market is substantial.

But founders consistently make the mistake of presenting the largest possible TAM number without showing they understand how they'll actually capture any of it. Saying the global healthcare market is $4 trillion doesn't help anyone. Saying "there are 180,000 independent physical therapy practices in the US, the average practice spends $40,000 per year on billing software, and no product currently serves this specific workflow," that helps. It shows you understand your specific slice of the market and have a credible path to it.

Investors at pre-seed are looking for a market that's big enough to matter and specific enough to win. Both matter. Big but vague is a yellow flag. Specific but tiny is a hard no.

Early traction signals, in order of strength

Not all traction is equal. Here's roughly how investors rank it, from strongest to weakest:

Paying customers, even at a discounted price, signal real demand better than anything else. Someone exchanging money for your product has made a real decision, not just expressed an opinion.

Active users with strong retention, people who come back without being reminded show that the product delivers real value.

Signed letters of intent or pilot agreements from real organizations, especially if someone had to get internal approval to sign them.

A waitlist that converts, not just signups, but signups who took the next action when you asked them to.

User interview feedback, useful for learning, weak as investor evidence on its own.

Friends and family enthusiasm, not evidence at all.

The further up that list your traction sits, the stronger your valuation position.

A credible go-to-market hypothesis

At seed stage specifically, investors want to see that you understand how customers will actually be acquired, not just that there's a market for what you're building.

This doesn't mean you need a fully built sales machine. It means you need to have tested at least one acquisition channel and have early data on what works. Founders who say "we'll grow through word of mouth and content" without any evidence that either is working are signaling that they haven't thought hard enough about distribution. Founders who say "we ran 200 cold emails, 18 booked calls, 4 converted to paid, here's what we learned" are showing they can execute and learn simultaneously.

showing they can execute and learn simultaneously.

How pre-seed and seed valuations actually get set

Here's the honest truth about how early stage valuations work in practice: they're often negotiated backward from ownership percentages rather than calculated forward from fundamentals.

An investor who needs to own 15–20% of your company to justify the time and board seat will back into a valuation based on the check size you're asking for. If you're raising $500k and they need 15%, your implied pre-money valuation is around $2.8M. The negotiation is then about whether your evidence justifies that number or whether they push for a lower valuation (and therefore more ownership) or you push for higher.

This is why knowing your comparables matters. What have similar companies, same stage, same sector, similar traction, raised at recently? That data gives you a defensible anchor in the conversation rather than leaving the investor to set the terms entirely.

According to Carta data, SAFEs (Simple Agreements for Future Equity) accounted for 92% of all pre-priced rounds as of late 2025. Most pre-seed deals don't set a hard valuation at all, they use a SAFE with a valuation cap, which sets the maximum valuation at which the investment converts to equity in a future round. Understanding the mechanics of your instrument matters as much as the number itself.

What the market looks like in 2026

Early-stage deal volume fell significantly in 2023 and remained selective through 2024 and into 2025. The founders getting funded in this environment are not necessarily smarter, they're the ones showing up with evidence rather than potential.

The bar has risen on what counts as a fundable pre-seed company. In 2021, a strong team and a big market could get you a check. In 2026, investors want to see that you've already done the first 10% of the work, that you've validated the problem with real users, that you have a specific insight the market doesn't have yet, and that you can execute quickly when given capital.

The good news: the bar being higher also means the noise level is lower. If you do the work to build genuine early evidence, you stand out clearly from the majority of founders who are still pitching ideas without proof.

The number you walk away with

A pre-seed valuation in 2026 typically falls somewhere between $1.5M and $10M pre-money, with the median closer to $5M–$8M for companies with meaningful early signals. The upper end of that range, $8M–$15M, goes to repeat founders with track records, companies with paying customers already, or businesses in sectors with exceptionally strong investor appetite right now (AI infrastructure, climate tech, and certain healthcare categories).

That range is a starting point, not a ceiling. The specific number depends on your evidence, your comparables, and how many investors you have in active conversations simultaneously. Competition among investors is still the single most reliable way to push a valuation higher, which means getting to multiple term sheets before accepting any one of them.

If you want to understand where your startup sits relative to real transaction data at your stage and in your sector, that's exactly what MergeX is built to show you.